Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mandorfer, M; Reiberger, T; Payer, BA; Ferlitsch, A; Breitenecker, F; Aichelburg, MC; Obermayer-Pietsch, B; Rieger, A; Trauner, M; Peck-Radosavljevic, M; Vienna HIV & Liver Study Group.
Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
AIDS. 2013; 27(2):227-232
Doi: 10.1097/QAD.0b013e32835aa161
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Obermayer-Pietsch Barbara
- Trauner Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Low 25-hydroxyvitamin D [25(OH)D] levels are commonly found in HIV-hepatitis C virus (HCV) coinfected patients and are associated with liver fibrosis. No association between 25(OH)D levels and response to pegylated interferon alpha-2a/2b plus ribavirin (PEGIFN + RBV) has yet been reported for HIV-HCV coinfected patients. Design: Epidemiological characteristics, HIV and HCV infection parameters, liver biopsies, as well as data on virologic response was available in 65 patients who received chronic hepatitis C (CHC) therapy with PEGIFN + RBV within a prospective trial. 25(OH)D levels were retrospectively assessed using stored screening serum samples obtained within 35 days prior to CHC treatment. Methods: According to their 25(OH)D levels, patients were assigned to the normal (>30 ng/ml; D-NORM), the insufficiency (10-30 ng/ml; D-INSUFF), or the deficiency (<10 ng/ml; D-DEF) group. HCV-GT 1/4, high HCV-RNA load (>6 x 10(5) IU/ml), advanced liver fibrosis (METAVIR F3/F4), and IL28B rs12979860non-C/C were considered as established risk factors for treatment failure in HIV-HCV coinfected patients. Results: Thirty-seven (57%) and 15 (23%) patients presented with D-INSUFF and D-DEF, respectively, whereas only 13 (20%) patients had normal 25(OH) D levels. Substantial differences in cEVR (D-NORM 92% vs. D-INSUFF 68% vs. D-DEF 47%; P = 0.008) and SVR (D-NORM 85% vs. D-INSUFF 60% vs. D-DEF 40%; P = 0.029) rates were observed between 25(OH)D subgroups. Especially in difficult-to-treat patients with multiple (three to four) established risk factors, low 25(OH)D levels were clearly associated with lower rates of SVR [patients without 25(OH)D deficiency 52% vs. D-DEF 0%; P = 0.012]. Conclusion: Low 25(OH)D levels may impair virologic response to PEGIFN + RBV therapy, especially in difficult-to-treat patients. Vitamin D supplementation should be considered and evaluated prospectively in HIV-HCV coinfected patients receiving CHC treatment. (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:227-232
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antiviral Agents - therapeutic use
- Coinfection -
- Drug Therapy, Combination -
- Female -
- HIV -
- HIV Infections - blood
- Hepacivirus -
- Hepatitis C, Chronic - blood
- Humans -
- Interferon-alpha - therapeutic use
- Male -
- Polyethylene Glycols - therapeutic use
- Prospective Studies -
- Randomized Controlled Trials as Topic -
- Recombinant Proteins - therapeutic use
- Ribavirin - therapeutic use
- Risk Factors -
- Vitamin D - blood
- Vitamin D Deficiency - blood
- Find related publications in this database (Keywords)
- coinfection
- hepatitis C virus
- HIV
- liver disease
- virologic response
- vitamin D deficiency